Hypoxia may require consideration for the pharmacology of CF therapies, including the CFTR modulators, as evidence of reduced CFTR expression and function with acute hypoxia (24–48 h) has been reported [18,19]. The gene discussed is CFTR; the disease is cystic fibrosis.